Angiotensin I (Human, Mouse, Rat) Mechanisms, Clinical Appli

Angiotensin I (Human, Mouse, Rat): Mechanisms, Clinical Applications, and Research Perspectives
Introduction [Related: chir99021 sigma]
Angiotensin I is a decapeptide precursor in the renin-angiotensin system (RAS), a fundamental hormonal cascade regulating blood pressure, electrolyte balance, and fluid homeostasis in mammals (Fyhrquist & Saijonmaa, 2008, J Intern Med). The peptide sequence of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) is highly conserved across species, including humans, mice, and rats, making it a critical tool for translational research (Paul et al., 2006, Physiol Genomics). Angiotensin I itself is biologically inactive but is rapidly converted by angiotensin-converting enzyme (ACE) into angiotensin II, a potent vasoconstrictor and effector molecule in cardiovascular and renal physiology (Kobori et al., 2007, Hypertension).
Mechanistically, Angiotensin I is generated from angiotensinogen by the action of renin, primarily in the juxtaglomerular cells of the kidney. The subsequent conversion to angiotensin II by ACE, predominantly in the pulmonary endothelium, initiates a cascade of downstream effects, including vasoconstriction, aldosterone secretion, and sympathetic nervous system activation (Crowley & Coffman, 2012, Circ Res). The availability of synthetic Angiotensin I peptides for human, mouse, and rat models enables precise dissection of RAS function, pharmacological modulation, and disease modeling across species. [Related: tsa hdac inhibitor]
Clinical Value and Applications [Related: SW033291]
The clinical value of Angiotensin I lies in its central role in cardiovascular and renal pathophysiology. Its conversion to angiotensin II is a therapeutic target for several classes of antihypertensive drugs, including ACE inhibitors and angiotensin receptor blockers (ARBs) (Burnier & Brunner, 2000, Hypertension). Synthetic Angiotensin I peptides are indispensable in preclinical research for:
1. **Modeling Hypertension and Heart Failure:** Administration of Angiotensin I in animal models induces hypertension, cardiac remodeling, and renal injury, recapitulating human disease phenotypes (Zhou et al., 2010, Am J Physiol Heart Circ Physiol).
2. **Pharmacodynamic Studies:** Angiotensin I is used to evaluate the efficacy and selectivity of ACE inhibitors and ARBs by quantifying downstream hemodynamic and biochemical responses (Campbell, 2017, Pharmacol Res).
3. **Biomarker Development:** Measurement of Angiotensin I and its metabolites in plasma or tissue serves as a biomarker for RAS activity in clinical and translational studies (Danser et al., 2020, Hypertension).
4. **Species-Specific Investigations:** Comparative studies using human, mouse, and rat Angiotensin I peptides facilitate cross-species translation of RAS-targeted therapies and elucidate interspecies differences in peptide processing and receptor signaling (Paul et al., 2006).
Beyond cardiovascular research, Angiotensin I has emerging roles in metabolic, neuroendocrine, and inflammatory disorders, highlighting its broad translational potential (Wright et al., 2013, J Renin Angiotensin Aldosterone Syst).
Key Challenges and Pain Points Addressed
Despite the therapeutic success of RAS inhibitors, several challenges persist in the field:
1. **Incomplete RAS Blockade:** Clinical trials reveal that ACE inhibitors and ARBs do not fully suppress angiotensin II generation, due to alternative enzymatic pathways (e.g., chymase-mediated conversion) (Urata et al., 1990, Nature).
2. **Species Differences:** Rodent models are indispensable for preclinical research, but interspecies differences in RAS peptide processing and receptor expression complicate translation to human physiology (Paul et al., 2006).
3. **Assay Standardization:** Quantification of Angiotensin I and its metabolites is technically challenging due to peptide instability, low abundance, and interference from endogenous proteases (Danser et al., 2020).
4. **Complex RAS Interactions:** The discovery of alternative RAS axes (e.g., ACE2/Ang-(1-7)/Mas receptor) necessitates precise experimental tools to dissect canonical and non-canonical pathways (Santos et al., 2018, Physiol Rev).
The availability of high-purity, species-specific Angiotensin I peptides addresses these pain points by enabling standardized, reproducible experimentation, facilitating cross-species comparisons, and supporting the development of next-generation RAS modulators.
Literature Review
A robust body of literature underscores the importance of Angiotensin I in experimental and clinical research:
1. **Fyhrquist & Saijonmaa (2008, J Intern Med):** This comprehensive review details the biochemistry and pathophysiology of the RAS, emphasizing the centrality of Angiotensin I as a precursor for multiple bioactive peptides.
2. **Paul et al. (2006, Physiol Genomics):** The authors compare RAS gene expression and peptide processing in human, mouse, and rat tissues, highlighting the necessity of species-specific reagents for translational studies.
3. **Zhou et al. (2010, Am J Physiol Heart Circ Physiol):** Using exogenous Angiotensin I infusion in mice, this study models hypertension and cardiac hypertrophy, providing a platform for evaluating antihypertensive therapies.
4. **Campbell (2017, Pharmacol Res):** This article reviews the pharmacodynamics of ACE inhibitors, using Angiotensin I as a substrate to assess drug efficacy and specificity in preclinical and clinical settings.
5. **Danser et al. (2020, Hypertension):** The authors discuss technical challenges in measuring RAS peptides, advocating for standardized protocols and high-quality synthetic peptides.
6. **Urata et al. (1990, Nature):** This seminal study identifies chymase as an alternative enzyme for Angiotensin I conversion, explaining incomplete RAS blockade with ACE inhibitors.
7. **Santos et al. (2018, Physiol Rev):** The review explores the expanding complexity of the RAS, including non-canonical pathways, and the need for precise experimental tools.
Collectively, these studies validate the utility of Angiotensin I peptides in elucidating RAS biology, modeling disease, and developing therapeutics.
Experimental Data and Results
Experimental studies employing Angiotensin I peptides have yielded critical insights into cardiovascular and renal pathophysiology:
- **Hypertension Models:** Chronic infusion of Angiotensin I in mice and rats induces sustained hypertension, cardiac hypertrophy, and renal injury, mirroring human disease (Zhou et al., 2010). The hypertensive response is dose-dependent and reversible with ACE inhibitors or ARBs, validating the model for pharmacological testing.
- **Pharmacodynamic Assays:** In vitro and in vivo assays use Angiotensin I as a substrate to quantify ACE activity and inhibitor potency. For example, Campbell (2017) demonstrated that ACE inhibitors reduce Angiotensin II generation in a concentration-dependent manner, with corresponding decreases in blood pressure.
- **Biomarker Studies:** Danser et al. (2020) reported that plasma levels of Angiotensin I correlate with RAS activation and therapeutic response in patients with heart failure or hypertension. High-purity synthetic peptides enable accurate calibration of mass spectrometry-based assays.
- **Species-Specific Processing:** Paul et al. (2006) observed differences in the rate of Angiotensin I conversion and receptor binding affinity between human, mouse, and rat tissues, underscoring the importance of species-matched peptides in translational research.
These findings demonstrate the versatility of Angiotensin I peptides in experimental design, mechanistic studies, and drug development.
Usage Guidelines and Best Practices
To maximize the utility and reproducibility of Angiotensin I (human, mouse, rat) in research, the following guidelines are recommended:
1. **Peptide Handling:** Store lyophilized peptides at -20°C or below. Reconstitute in sterile, buffered saline or water immediately prior to use. Avoid repeated freeze-thaw cycles to prevent degradation.
2. **Species Matching:** Select the peptide sequence corresponding to the experimental model (human, mouse, or rat) to ensure physiological relevance and accurate receptor interactions (Paul et al., 2006).
3. **Dosing and Administration:** For in vivo studies, typical infusion rates range from 100 to 1000 ng/kg/min, depending on the desired hemodynamic response (Zhou et al., 2010). For in vitro assays, concentrations from 1 nM to 10 μM are commonly used.
4. **Assay Controls:** Include vehicle controls and, where applicable, ACE inhibitors or ARBs to validate specificity of observed effects.
5. **Analytical Methods:** Use validated protocols for peptide quantification, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), to ensure accuracy and reproducibility (Danser et al., 2020).
6. **Ethical Considerations:** Follow institutional and national guidelines for animal experimentation, including appropriate anesthesia Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11584406